logologo
QuantliQuantli

PharmaCyte Biotech Inc

PMCB

NASDAQ

Biotechnology

$0.55

USD

0.00 (+0.18%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $5.90M

Volume 131.5K

Price (USD)
Price (USD)

About PharmaCyte Biotech Inc

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

CEO

Mr. Joshua Silverman

HQ

Las Vegas, NEVADA, US

Founded

2003

Employees

2

Key Metrics

3 metrics our research team weighs before forming a view on PMCB.

Based on Quantli research · SEC filings · as of Q4 2026

METRIC

VALUE

CHANGE

TREND (3Y)

ROE (TTM)

-56.2%

-115.3 pp

EPS Growth (TTM)

-632.9%

Free Cash Flow (TTM)

$-5.15M

Financial Snapshot

Full Financials

Revenue

$0

YoY

Gross Margin

YoY

Net Income

$-19.42M

-163.4%

YoY

Operating Cash Flow

$-5.15M

-73.0%

YoY

Key Statistics

Open

$0.56

Previous Close

$0.55

Day Range

$0.54 - $0.57

52 Week Range

$0.53 - $1.51

Volume

131.5K

Average Volume (10 Days)

160.0K

Dividend Yield

Valuation Measurement

Market Cap

$5.90M

P/E Ratio (TTM)

Price / Book

0.17

Financial Highlights

Return on Assets

-41.5%

Return on Equity

-56.2%

Revenue (TTM)

$0

Net Income (TTM)

$-19.42M

Diluted EPS (TTM)

-$4.53

Total Cash (MRQ)

$18.60M

Levered FCF (TTM)

$-5.15M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Go deeper on PMCB

Similar Stocks

ENSC

Ensysce Biosciences Inc

$0.4000

+14.8%

GOVX

GeoVax Labs Inc

$0.7200

+0.0%

ERNA

Ernexa Therapeutics Inc

$4.27

-0.7%

LABT

Lakewood-Amedex Biotherapeutics Inc

$2.27

-2.6%

BOLT

Bolt Biotherapeutics Inc

$3.35

+4.4%

BRTX

BioRestorative Therapies Inc

$0.2300

+2.6%

ACXP

Acurx Pharmaceuticals Inc

$1.40

-5.7%

XBIO

Xenetic Biosciences Inc

$3.28

-0.3%

CDIO

Cardio Diagnostics Holdings Inc

$2.04

+1.5%

DRMA

Dermata Therapeutics Inc

$1.46

-7.0%

Earnings Calendar

Next Earnings

Estimated Q1 Release

Sep 14